Citations

Clear

949 citation(s) found for "Li, Bryan".

Abstract 4139651: Cardiac Rehabilitation Following Thoracic Aortic Dissection Surgery: A Multi-Center Retrospective Study
Heybati, Kiyan , Ochal, Domenic, Poudel, Keshav , Zuberi, Eric , Tayon, Kevin , Farres, Sam, Landolfo, Kevin, Shapiro, Brian P. , Dineen, Elizabeth H. , Taylor, Bryan J. , Landolfo, Kevin

Mayo Clinic

Circulation | November 14, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4139651 Get It

Background: Despite expert opinion recommending patient-tailored cardiac rehabilitation (CR) after acute aortic dissection, both patient participation in CR and the associated risk factor modification after CR following aortic dissection repair are poorly understood. Objectives: To describe the characteristics of patients referred to CR, as well as the enrollment rate and outcomes of those referred to CR following thoracic aortic dissection. Methods: We reviewed electronic health records of adults (≥18) discharged alive following thoracic aortic dissection surgery across the Mayo Clinic Enterprise (01/01/2020-11/15/2022) with follow-up to 05/15/2024 (IRB #24-001141). Data are presented using summary statistics. Results: During the study period, 85 patients were included (median [IQR] age: 65 [50-75] years; 40% female; Table 1 ). Across 84% (N=71) who were referred to CR at discharge, 55% (N=39) enrolled. In those patients referred versus not referred to CR, the prevalence of type A dissection (75% vs. 43%), end-organ involvement (27% vs. 0%), and underlying CAD (54% vs. 21%) were greater while current tobacco use (9% vs. 29%) was lower. Of those enrolled at Mayo Clinic (N=16), CR was started 35 (28-65) days following surgery. These patients completed 21 (13-30) CR sessions at an exercise intensity of 59% (50-65%) maximum predicted heart rate. CR was discontinued in 44% (N=7) due to non-cardiac reasons ( Table 2 ). Of the 9 patients who completed CR, general health status (Dartmouth index: 19 [17-21] vs. 26 [22-34]), depressive symptoms (PHQ-9: 1 [0-1] vs. 4 [1-4]), and exercise capacity (6MWT: 214 [196-244] vs. 384 [305-597] meters) improved ( Table 2 ). There were no reported complications or deaths, with stable aortic sizes reported at 18 months. Conclusions: CR improves functional capacity and well-being without complications in patients after thoracic aortic dissection surgery. Further investigation is needed to better assess CR efficacy and usage in this population.
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024
Thompson, John A. , Schneider, Bryan J. , Brahmer, Julie R. , Zaid, Mohammad Abu , Achufusi, Amaka, Armand, Philippe , Bermas, Bonnie L. , Braaten, Tawnie , Chokshi, Saurin , Crees, Zachary , Davies, Marianne, Deng, Changchun , Gesthalter, Yaron , Jallouk, Andrew , Khalil, Maya, Marr, Alissa , McGettigan, Suzanne , Medina, Theresa , Mohindra, Nisha , Patel, Sandip Pravin , Prosek, Jason, Reddy, Sunil , Reid, Pankti , Ryder, Mabel , Shofer, Scott , Sosman, Jeffrey A. , Zucker, Stephen D. , Lyons, Megan , Hang, Lisa, Ryder, Mabel , Berkenstock, Meghan , Bermas, Bonnie , Budde, Lihua E. , Jain, Michael D. , Jain, Prantesh , Kaffenberger, B , Lechner, Melissa G , Li, Tianhong , McPherson, Jordan P. , Medina, Theresa Michelle , Olszanski, Anthony J. , Oluwole, Olalekan O. , Ryan, John, Salman, Huda , Santomasso, Bianca , Wang, Yinghong , Zaha, Vlad G , Awotiwon, Ajibola

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 13, 2024 | Volume: 22 | Issue: 9 | Pages: 582-592

10.6004/jnccn.2024.0057 | PMID 39536465 Get It

The NCCN Guidelines for the Management of Immunotherapy-Related Toxicities are intended to provide oncology practitioners with guidance on how to manage the wide-ranging and potentially fatal toxicities that may occur with cancer immunotherapy. The guidelines address immune-related adverse events related to immune checkpoint inhibitors, CAR T-cell therapies, and lymphocyte engagers (which include T-cell–engaging bispecific antibodies). These NCCN Guidelines Insights highlight recent guideline updates pertaining to the management of emerging toxicities related to cancer immunotherapy.
NCOG-29. HIGHER HYPOTHALAMIC RADIATION DOSE AND FEMALE GENDER ARE RELATED TO HIGHER SELF-REPORTED FATIGUE
Neth, Bryan J. , Alden, Eva , Uhm, Joon H. , D’Andre, Stacy D. , Amundson, A., Vora, Sujay A., Mahajan, Anita , Brown, Paul D. , Breen, William G. , Neth, Byran J. , Sener, Uğur , Burns, Terry C. , Routman, David M. , Trifiletti, Daniel M. , Laack, Nadia N.

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii230-viii231

10.1093/neuonc/noae165.0911 Get It

Abstract BACKGROUND Fatigue is among the most common symptoms managed by patients with cancer. Hypothalamic pituitary axis dysfunction has an established role in a subset of patients with fatigue. Our primary aim was to longitudinally assess the impact of hypothalamic radiation exposure to patient self-reported fatigue. METHODS We included a sample of patients who received radiation therapy treated at a single institution from 2014-2024. The PROMIS-10 questionnaire (“How would you rate your fatigue on average,” scale 1-5) was used in standard clinical practice, with measures from 6 time points over 2 years. We performed descriptive statistics. Linear mixed models were used to assess the impact of hypothalamic radiation dose on fatigue scores. Mixed models were controlled for gender, age, time, tumor category (CNS vs. non-CNS), and modality (photon vs. proton). Models were fit with random intercepts for each Patient ID. RESULTS 1092 patients (43% female) with a median age of 54 years (range: 18-92) were included. Most patients were treated for CNS cancer (76%), with about 50% each photon and proton. Median hypothalamus radiation dose was 1306 cGy (range: 0.01-6138). Mean baseline fatigue (2.4) increased after treatment (2.7) remaining elevated at 3- and 6-months post-treatment (2.6, 2.5), returning near baseline at 1- and 2-years post-treatment (2.4, 2.3). Higher radiation dose (Estimate (SE): 0.014 (0.006), p=0.0266) and CNS cancer treatment (0.11 (0.051), p=0.0319) were significant predictors of higher fatigue in the mixed model. Male patients (-0.16 (0.042), p=0.0001) and time (-0.003 (0.0016), p=0.0398) were associated with lower fatigue. Age and treatment modality were not significant predictors of fatigue. CONCLUSIONS We found that higher hypothalamic radiation dose was related to more self-reported fatigue, which peaked by 6 months. This effect was seen more prominently in female patients and those treated for CNS disease. Treatment modality and age did not influence fatigue scores.
CSIG-29. BRAF INHIBITOR THERAPY IN BRAF-MUTATED PRIMARY BRAIN TUMORS: A SINGLE-CENTER EXPERIENCE
Baykal, Duru, Ser, Hazal, Neth, Bryan J. , Uhm, Joon H. , Ruff, Michael W. , Wilson, Jessica , Yan, Elizabeth , Meyer, Fredric B. , Celda, María Peris, Neth, Byran J. , Baykal, Duru, White, Jessica B. , Sarkaria, Jann N. , Sener, Uğur

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii70-viii70

10.1093/neuonc/noae165.0278 Get It

Abstract BACKGROUND BRAF pathway alterations are frequent in glial/neuroepithelial tumors. BRAF-targeted therapy with BRAF inhibitors (BRAFi) and/or MEK inhibitors (MEKi) has proven efficacy in clinical trials, though mainly enrolling pediatric patients. We sought to investigate real-world data for adult patients with BRAF-pathway mutant glial/neuroepithelial neoplasms treated with BRAFi/MEKi. METHODS Adults with BRAF-pathway mutated glial/neuroepithelial neoplasms treated with BRAFi/MEKi were retrospectively reviewed. RESULTS Five patients (n=4 female, median age at diagnosis 36) were identified (tumor types: glioblastoma n=1, high-grade astrocytoma with epithelioid features n=1, low-grade neuroepithelial tumor n=1, pilocytic astrocytoma n=1, pleomorphic xanthoastrocytoma n=1). Four had BRAF V600E and one had NF1 p.S2687Cfs*5 mutant tumors. Prior to targeted therapy initiation, patients underwent a median 2.4 treatments including surgery (n=4), radiation therapy (n=4), chemotherapy (temozolomide n=4; carboplatin/vincristine n=1). BRAF-targeted therapies included dabrafenib/trametinib (n=4), binimetinib/encorafenib (n=2), binimetinib (n=2). One NF1-mutant glioblastoma received binimetinib followed by binimetinib/bevacizumab. Median BRAFi/MEKi treatment was 15.2 months (range: 6-36 months). Toxicities included leukopenia (n=3), peripheral edema (n=1), reduced ejection fraction (n=1), skin rash (n=5), transaminitis (n=1) with all patients requiring dose reductions and 3 cases requiring discontinuation. Among patients where BRAFi/MEKi was discontinued due to toxicity, 2 received other treatments at progression, then switched to a different BRAFi/MEKi combination, which they tolerated (duration 6-10months). Best radiographic response was partial response, noted in 3 patients treated with dabrafenib/trametinib. Four patients remain alive and continue BRAFi/MEKi. CONCLUSIONS In this cohort of heavily-pretreated patients with glial/neuroepithelial neoplasms, BRAF-targeted therapy was associated with durable responses. Interestingly, two patients who were unable to tolerate one combination of BRAFi/MEKi were able to tolerate a different combination with sustained response. Our findings support ongoing use of BRAF targeted therapy for CNS tumors. Optimal timing and duration of treatment requires further prospective evaluation in adult patients.
CTNI-82. BELZUTIFAN TREATMENT OF VHL-ASSOCIATED CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMA
Thomsen, Anna, Valerius, Allison , Uhm, Joon H. , Ruff, Michael W. , Baykal, Duru, Caron, Samantha, Pichurin, Pavel N. , Neth, Bryan J. , Neth, Byran J. , Baykal, Duru, White, Jessica B. , Webb, Mason , Sener, Uğur

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii116-viii116

10.1093/neuonc/noae165.0449 Get It

Abstract Von Hippel-Lindau (VHL) disease is caused by pathogenic variants in the VHL gene. Abnormal function of VHL protein leads to accumulation of HIF-α and the engagement of hypoxia-sensitive genes with oncogenic effects. VHL is associated with tumors in multiple organs. Belzutifan is an oral selective inhibitor of hypoxia-inducible factor 2 alpha. Belzutifan was approved in 2021 as a targeted therapy for VHL-associated CNS hemangioblastomas, renal cell carcinomas, and pancreatic neuroendocrine tumors. Here, we report on our institutional clinical experience with belzutifan for VHL-associated CNS hemangioblastomas. From October 2021 to May 2024, thirteen adults (9 female, 4 male, median age 40) were treated. Median duration of therapy was 24 months. Seven had a partial radiographic response after median of 3 months; one patient had a partial response; 1 patient had progressive disease on belzutifan. Four patients have been taking belzutifan for less than 3 months, and do not have follow-up imaging to assess response. The most common adverse effect was fatigue (7 patients). Four patients experienced anemia and 2 experienced hypoxia. Three patients discontinued belzutifan due to adverse effects. One patient had to take multiple medication pauses, due to seizure and kidney injury, but resumed treatment with dose reduction. Nine patients remain on therapy. Based on this data, belzutifan is often well-tolerated and associated with durable radiographic responses. Toxicity profile among our patients was similar to that encountered in the clinical trial leading to approval of the agent. These findings provide real-world data supporting continued use of belzutifan in this patient population, with an awareness of potential adverse reactions. Future studies should assess continued radiographic response, sex differences, and effects after long-term use.
INNV-27. TEMOZOLOMIDE FOR PATIENTS WITH AGGRESSIVE PITUITARY TUMORS: A CASE SERIES
Baykal, Duru, Ser, Hazal, Uhm, Joon H. , Ruff, Michael W. , Neth, Bryan J. , Giannini, Caterina, Erickson, Dana , Neth, Byran J. , White, Jessica B. , Baykal, Duru, Lachance, Daniel Honore , Gompel, Jamie J. Van , Raghunathan, Aditya , Sener, Uğur

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii174-viii174

10.1093/neuonc/noae165.0689 Get It

Abstract BACKGROUND Pituitary adenomas are often effectively managed with medical therapy, surgery, and radiation therapy. However, up to 15% of pituitary neoplasms exhibit rapid growth, invasive behavior, or, rarely, metastasize despite optimal standard treatments. Temozolomide is associated with a survival benefit for patients with these aggressive pituitary tumors. METHODS We present a case series of 8 patients with an aggressive pituitary tumor (APT) or pituitary carcinoma (PC) treated with temozolomide. RESULTS Eight patients (3 female, median age at diagnosis 44) with APT (n=6) or PC (n=2) were treated. A variety of pituitary tumor types were represented (1 prolactinoma, 5 corticotroph adenomas, 1 gonadotroph adenoma, 1 thyrotropinoma). Prior to temozolomide initiation, patients underwent a median 5 treatments including medical management (n=4), surgery (n=7), radiation therapy (n=7). Temozolomide was started at median 3.5 recurrence. Median treatment duration was 6 cycles (n=6, 150-200 mg/m2 days 1-5, 28-day cycles; n=1, 75 mg/m2, days 1-21, 28-day cycles). Seven patients experienced progression after temozolomide treatment, median progression-free survival (PFS) was 4 months. One patient remains on treatment, progression-free at 5 months. MGMT methylation status was assessed for 3 tumors. Among 2 patients with MGMT promoter methylated tumors, PFS was 4 months for one patient, the other remains on treatment. For one patient with MGMT promoter unmethylated corticotroph adenoma, PFS was 9 months. No ≥ grade 4 toxicities were noted. Most common toxicities were nausea (n=5), thrombocytopenia (n=3), and fatigue (n=2). CONCLUSION In this group of heavily pretreated patients, temozolomide monotherapy was well-tolerated and associated with median PFS of 4 months. Interestingly, PC patients had longer PFS at 9 months and 24 months. Our findings support use of single-agent temozolomide chemotherapy for patients with APT/PC, but further prospective analysis is needed to identify patients more likely to benefit from treatment and optimal timing of chemotherapy initiation.
Identifying important and feasible primary care structures and processes in the US healthcare system: a modified Delphi study
Albert, Stephanie L. , Kwok, Lorraine , Shelley, Donna , Paul, Maggie M, Blecker, Saul , Nguyen, Ann , Harel, Daphna , Cohen, Deborah J. , Berry, Carolyn A. , Paul, Maggie M, Cleland, Charles M. , Weiner, Bryan Jeffrey , Damschroder, Laura J.

Mayo Clinic

BMJ Open | November 9, 2024 | Volume: 14 | Issue: 11 | Pages: e082989

10.1136/bmjopen-2023-082989 | PMID 39521461 Get It

Objective To identify primary care structures and processes that have the highest and lowest impact on chronic disease management and screening and prevention outcomes as well as to assess the feasibility of implementing these structures and processes into practice. Design A two-round Delphi study was conducted to establish consensus on the impact and feasibility of 258 primary care structures and processes. Participants 29 primary care providers, health system leaders and health services researchers in the USA. Outcomes Primary outcomes were (1) consensus on the impact of each structure and process on chronic disease management and screening and prevention outcomes, separately and (2) consensus on feasibility of implementation by primary care practices. Results Consensus on high impact and feasibility of implementation was reached on four items for chronic disease management: ‘Providers use motivational interviewing to help patients set goals’, ‘Practice has designated staff to manage patient panel’, ‘Practice has onsite providers or staff that speak the most dominant, non-English language spoken by patients’ and ‘Practice includes mental health providers and/or behavioural health specialists in care team’ and seven items for screening and prevention: ‘Practice utilizes standing protocols and orders’, ‘Practice generates reports to alert clinicians to missed targets and to identify gaps in care, such as overdue visits, needed vaccinations, screenings or other preventive services’, ‘Practice has designated staff to manage patient panel’, ‘Practice sets performance goals and uses benchmarking to track quality of care’, ‘Practice uses performance feedback to identify practice-specific areas of improvement’, ‘Practice builds quality improvement activities into practice operations’ and ‘Pre-visit planning data are reviewed during daily huddles’. Only ‘Practice has designated staff to manage patient panel’ appeared on both lists. Conclusion Findings suggest that practices need to focus on implementing mostly distinct, rather than common, structures and processes to optimise chronic disease and preventive care.
Vestibular Schwannoma Koos Grade I International Study of Active Surveillance Versus Stereotactic Radiosurgery: The VISAS-K1 Study
Bin-Alamer, Othman , Peker, Selçuk , Samancı, Yavuz , Pelcher, Isabelle , Begley, Sabrina , Goenka, Anuj , Schulder, Michael , Tourigny, Jean-Nicolas, Hamel, Andréanne, Briggs, Robert G. , Yu, Cheng , Zada, Gabriel , Giannotta, Steven L., Palque, Sarai, Kumar, Narendra , Rogowski, Brandon, Shepard, Matthew J., Warnick, Ronald E. , Dayawansa, Sam , Vasconcellos, Fernando De Nigris , Bernstein, Kenneth , Sheehan, Jason P. , Johnson, Bryan A, Sheehan, Jason , Bin-Alamer, Othman , Abou‐Al‐Shaar, Hussam , Mathieu, David , Giannotta, Steven L. , Speckter, Herwin , Tripathi, Manjul , Kumar, Saurabh , Kaur, Rupinder , Johnson, Bryan A., Trifiletti, Daniel M. , Mashiach, Elad , Schnurman, Zane , Alzate, Juan Diego , Kondziolka, Douglas

Mayo Clinic

Neurosurgery | November 6, 2024 | Volume: 96 | Issue: 1 | Pages: 41-49

10.1227/neu.0000000000003215 | PMID 39503441 Get It

BACKGROUND AND OBJECTIVE: This investigation evaluates the safety and efficacy of stereotactic radiosurgery (SRS) vs observation for Koos grade I vestibular schwannomas (VS). METHODS: In a multicenter study, we retrospectively analyzed data of patients with Koos grade I VS who underwent SRS (SRS group) or were observed (observation group). Propensity score matching was used to equilibrate demographics, tumor size, and audiometric data across groups. The outcome analyzed included tumor control, preservation of serviceable hearing, and neurological function. RESULTS: The study matched 142 patients, providing a median follow-up period of 36 months. SRS significantly enhanced tumor control compared with observation, with a 100% control rate at both 5- and 8-year marks in the SRS group vs 48.6% and 29.5% in the observation group at the same time intervals, respectively ( P < .001). Preservation of serviceable hearing outcomes between groups showed no significant difference at 5 and 8 years, ensuring a comparable quality of auditory function (SRS 70.1% vs observation 53.4% at 5 years; P = .33). Furthermore, SRS was associated with a reduced likelihood of tinnitus (odds ratio [OR] = 0.46, P = .04), vestibular dysfunction (OR = 0.17, P = .002), and overall cranial nerve dysfunction (OR = 0.49, P = .03) at last follow-up. CONCLUSION: SRS management of patients with Koos grade I VS was associated with superior tumor control and reduced odds for cranial nerve dysfunction, while not compromising hearing preservation compared with observation. These findings support the safety and efficacy of SRS as a primary care approach for this patient population.
Vestibular Schwannoma Koos Grade II International Study of Active Surveillance Versus Stereotactic Radiosurgery: The VISAS-K2 Study
Bin-Alamer, Othman , Peker, Selçuk , Samanci, Yavuz, Pelcher, Isabelle , Begley, Sabrina , Goenka, Anuj , Schulder, Michael , Tourigny, Jean-Nicolas, Hamel, Andréanne, Briggs, Robert G. , Yu, Cheng , Zada, Gabriel , Giannotta, Steven L., Palque, Sarai, Kumar, Narendra , Rogowski, Brandon, Shepard, Matthew J., Warnick, Ronald E. , Dayawansa, Sam , Vasconcellos, Fernando De Nigris , Bernstein, Kenneth , Sheehan, Jason P. , Samancı, Yavuz , Johnson, Bryan A, Sheehan, Jason , Bin-Alamer, Othman , Abou‐Al‐Shaar, Hussam , Mathieu, David , Giannotta, Steven L. , Speckter, Herwin , Tripathi, Manjul , Kumar, Saurabh , Kaur, Rupinder , Johnson, Bryan A., Trifiletti, Daniel M. , Mashiach, Elad , Schnurman, Zane , Alzate, Juan Diego , Kondziolka, Douglas

Mayo Clinic

Neurosurgery | November 6, 2024 | Volume: 96 | Issue: 1 | Pages: 50-58

10.1227/neu.0000000000003216 | PMID 39503444 Get It

BACKGROUND AND OBJECTIVES: This study assessed the efficacy and safety of stereotactic radiosurgery (SRS) in comparison with watchful waiting for managing Koos grade II vestibular schwannomas (VS). METHODS: A retrospective, multicentric analysis was conducted, focusing on patients with Koos grade II VS who either received SRS (SRS group) or were observed (observation group). To ensure comparability between groups, propensity score matching was used, including factors such as demographic characteristics, tumor dimensions, and hearing assessments. The primary end points examined were tumor control, maintenance of serviceable hearing, and neurological outcomes. RESULTS: A total of 92 patients were equally matched across both cohorts, with a median follow-up of 37 months for the SRS group and 27.5 months for those observed. The SRS cohort exhibited superior tumor control over observation across 3, 5, and 8 years, achieving a 100% control rate vs 47.9%, 40.1%, and 34.3% for the observation group at these time intervals, respectively ( P < .001). Serviceable hearing preservation rates were comparable between the 2 groups throughout 3, 5, and 7 years (72.9% for SRS vs 65.4% for observation at 3 years; P = .86). Moreover, SRS management correlated with a lower incidence of vestibular symptoms (odds ratio = 0.11, P = .002), with no significant disparity in the deterioration of cranial nerve (CN) V or CN VII functions. Notably, the likelihood of experiencing any CN impairment was significantly diminished in the SRS cohort (odds ratio = 0.47, P = .04). CONCLUSION: For patients with Koos grade II VS, SRS offers superior tumor control rate and a lower risk of CN dysfunction without sacrificing hearing preservation.
Human Stem Cell–Derived Cardiomyocytes Integrate Into the Heart of Monkeys With Right Ventricular Pressure Overload
Scholz, Jodi A. , Secreto, Frank J., Wobig, Joan, Kurian, Joe R, Hagen, Clint , Zinnen, Alexandra D. , Vu, Don, Johnson, Steven J., Cetta, Frank , Qureshi, M. Yasir , Reams, Rachel Y., Cannon, Bryan C. , Heyer, Christina M., Chang, Min‐Hwang , Fadra, Numrah, Coonen, Jennifer , Simmons, Heather A. , Mejía, Andrés , Hayes, Jennifer M. , Basu, Puja , Capuano, Saverio , Bondarenko, Viktoriya, Metzger, Jeanette M. , Nelson, Timothy J., Scholz, Jodi, Qureshi, Muhammad Y , Cannon, Bryan, Emborg, Marina E , Vu, Don, Johnson, Steven J., Nelson, Timothy J.

Mayo Clinic

Cell Transplantation | November 2, 2024 | Volume: 33 | Issue: No issue available | Pages: No page available

10.1177/09636897241290367 | PMID 39487759 Get It

Cardiac ventricular pressure overload affects patients with congenital heart defects and can cause cardiac insufficiency. Grafts of stem cell–derived cardiomyocytes are proposed as a complementary treatment to surgical repair of the cardiac defect, aiming to support ventricular function. Here, we report successful engraftment of human induced pluripotent stem cell–derived cardiac lineage cells into the heart of immunosuppressed rhesus macaques with a novel surgical model of right ventricular pressure overload. The human troponin+ grafts were detected in low-dose (2 × 10 6 cells/kg) and high-dose (10 × 10 6 cells/kg) treatment groups up to 12 weeks post-injection. Transplanted cells integrated and progressively matched the organization of the surrounding host myocardium. Ventricular tachycardia occurred in five out of 16 animals receiving cells, with episodes of incessant tachycardia observed in two animals; ventricular tachycardia events resolved within 19 days. Our results demonstrate that grafted cardiomyocytes mature and integrate into the myocardium of nonhuman primates modeling right ventricular pressure overload.